Currently there is no description available for Alejandro Cravioto.
“[We] came to the conclusion that there is enough evidence of safety and the capacity of the vaccine to prevent severe disease or symptomatic and hospitalized cases up to 79 per cent. The information we have for people over 60 is still very scarce. There is no reason to think that the vaccine would behave differently in this older age group.”
07 May 2021
3
3
Read More
